Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX Days Sales Outstanding is 0.00 as of Jun. 2026. The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 497511.94% on this metric.
The historical rank and industry rank for Imagion Biosystems's Days Sales Outstanding or its related term are showing as below:
During the past 9 years, Imagion Biosystems's highest Days Sales Outstanding was 164.25. The lowest was 11.80. And the median was 48.56.
ASX:IBX's Days Sales Outstanding is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 67.59 * Ranked among companies with meaningful Days Sales Outstanding only.
Imagion Biosystems's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Imagion Biosystems (ASX:IBX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Imagion Biosystems Days Sales Outstanding Related Terms
Imagion Biosystems Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IBX vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's Days Sales Outstanding falls into.
Imagion Biosystems Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (ASX:IBX) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Imagion Biosystems and its competitors. Over the past decade, Imagion Biosystems' Days Sales Outstanding has ranged from 11.80 to 164.25. According to the industry distribution chart, Imagion Biosystems ranks #999999 out of 201 companies in the Medical Diagnostics & Research industry.
Is Imagion Biosystems' Days Sales Outstanding too high?
Imagion Biosystems' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 11.80 to a high of 164.25. Based on the distribution chart, Imagion Biosystems ranks #999999 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #999999 out of 201 companies for Days Sales Outstanding. This places Imagion Biosystems in the lower half of its industry. The industry median Days Sales Outstanding is 67.59. Historically, Imagion Biosystems' own Days Sales Outstanding has ranged from 11.80 to 164.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 99.3% below its estimated fair value. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
